Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.

PLoS One · 2022 · PMC8836314 · PMID 35148357

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Ketone levels increased after empagliflozin treatment, but the increment did not reach statistical significance (0.073) and the measurements were influenced by carry-over effect.

also in 111,027 other papers

a clear trendno p-value reported

We observed a clear trend of reduction in cardiovascular biomarkers after empagliflozin treatment and increased levels after the placebo period.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.